EN FR ABOUT KURMA TEAM OUR FUNDS PORTFOLIO NEWS VIDEOS CONTACT Crédit photo : Institut Pasteur Filter by year 2021 2020 2019 2018 2017 2016 2015 2014 Filter by participations Kurma Partners Œ ABM Pharmareva Œ AM Pharma Œ Amolyt Pharma Œ Argobio Studio Œ Arkhn Œ Asarina Pharma Œ Asceneuron Œ Auris Medical Œ BioSerinity Œ BliNK Œ Cardiologs Œ Coave Therapeutics Œ Corlieve Therapeutics Œ DAMAE Medical Œ Deepull Œ DNA Script Œ Dynacure Œ Emergence Œ Ermium Therapeutics Œ FeetMe Œ Flamingo Therapeutics Œ ImCheck Œ IO Biotech Œ Kiro Œ Kurma Accélération Œ Lucine Œ MedLumics Œ Meiogenix Œ Mila Œ Minroyx Œ Omnidoc Œ Orphazyme Œ OxThera Œ PathoQuest Œ Pharvaris Œ Safe Orthopaedics Œ Sensome Œ Smartcatch Œ StatDx Œ STEP Pharma Œ Stilla Technologies Œ Synendos Therapeutics Œ Tacalyx Œ Talix Œ Vico Therapeutics Œ Vivet Therapeutics Œ Xeltis Œ Zealand Pharma 25/11/2021 Asarina Pharma AB (publ) Q3 Report 2021 released Asarina Pharma CEO Peter Nordkild: “While we made progress in several areas during Q3 2021, it was frustrating for us that our phase IIa study in Tourette Syndrome was delayed. We now expect our first patients to be included in the Study in December.” FINANCIAL HIGHLIGHTS Signif ... 10/11/2021 Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku Nippon Shinyaku secures an exclusive option to acquire all development and commercial rights to advance DYN101 for the treatment of myotubular and centronuclear myopathy in Japan; Dynacure retains rights for rest of world STRASBOURG, France and PHILADELPHIA and KYOTO, Nov. 10, 2021 /PRNewswire/ ... 09/11/2021 PathoQuest closes up to €15 million Series B financing round led by growth investor SHS Capital This funding round allocated in tranches, will strengthen PathoQuest’s position as a leading NGS-based biosafety CRO for the biopharmaceutical industry. Paris, FRANCE, Tübingen, GERMANY - November 9th, 2021 - PathoQuest, a pioneer in the quality control of biologics using Next-G ... 02/11/2021 Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021 Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data. Mataró, Barcelona, Spain, November 3, 2021 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the deve ... 26/10/2021 PathoQuest, recipient of French Investment Program, expands NGS-based portfolio of quality control tests for biologics Paris, FRANCE - October, 25 2021 – PathoQuest, a pioneer in the quality control of biologics using Next-Generation Sequencing (NGS), announced today that it has been awarded €0.85M from the French Investment Program for the Future (Programme d’Investissement d’Avenir - PI ... 15/10/2021 ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine Publication underscores ImCheck’s pioneering role in Vγ9Vδ2 T cell-based immunotherapy capable of bridging to the adaptive antitumor immune response through a novel family of immune checkpoint targets Evaluation details ICT01’s progression from bench to bedside ... 12/10/2021 Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board • Dr. Olivier Danos PhD, is currently Chief Scientific Officer of RegenxBio • Frederic Chereau MBA, is currently President and CEO of LogicBio Paris, France, 12th October 2021 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on develop ... 04/10/2021 DeepUll Appoints Richard Ivey to its Board of Directors Diagnostics industry veteran with forty years’ experience to support DeepUll in its continued development of its early sepsis identification system BARCELONA, Spain - October 4 2021 - DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the e ... 29/09/2021 Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences OGA inhibitors offer multimodal mechanism of action with potential for multiple approaches to clinical development in Alzheimer’s and Parkinson’s disease Lausanne, SWITZERLAND and San Francisco, CA, USA, 30 September 2021 - Asceneuron SA, a clinical stage company dedicated to target ... 28/09/2021 PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology (Stockholm, 28 September 2021.) The publication of Asarina Pharma’s phase IIb study, including a post hoc analysis into Sepranolone for PMDD (Premenstrual dysphoric disorder), demonstrates that Sepranolone in a 10 mg dose did have a significant treatment effect compared with placebo, when exam ... 24/09/2021 Eurazeo aims to consolidate its position as a major player in health care financing by raising its stake in Kurma Partners, a venture capital firm focused on medical innovation and biotechnology Paris, September 23, 2021 - Eurazeo today announced its intention to raise its stake in Kurma Partners, a French venture capital firm specializing in biotechnology and medical innovation, to 70.6%. This transaction coincides with Kurma’s launch of a third investment strategy, Growth Opportunit ... 07/09/2021 AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive ... 19/08/2021 Asarina Pharma AB (publ) Q2 Report 2021 released Asarina Pharma CEO Peter Nordkild: “Q2 2021 was a difficult quarter for us and our shareholders. It was also a definitively transformative one. The failure of our Phase IIa study in Menstrual Migraine coincided with the approval of our CTA in Tourette syndrome by the Danish Medicines Agency, a ... 08/07/2021 Amolyt Pharma Announces Appointment of Two Directors Elisabeth Svanberg, M.D., Ph.D. brings extensive experience in the development of therapeutics for under-served endocrine, metabolic and other diseases James Hindman has over 30 years of senior financial experience in the pharmaceutical, biologics and medical device industries Lyon, Fr ... 28/06/2021 Unilabs France accélère sa transformation digitale et révolutionne l'expérience des résultats de biologie médicale en signant un partenariat avec la start-up Kiro Paris, le 28 juin 2021 : Unilabs France - la plus importante filiale du Groupe Unilabs, leader européen du diagnostic médical et un acteur majeur de la biologie médicale en France, et Kiro, start-up qui développe une plateforme d'intelligence artificielle au service ... 22/06/2021 UniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE) Expands uniQure’s Pipeline of Innovative Gene Therapies to Treat Neurological Disorders Strengthens uniQure’s Global Leadership in the Development of Gene Therapies that Employ miRNA Silencing Technology Large Opportunity Targeting an Estimated 1.3 million TLE Patients in the U.S. ... 15/06/2021 DNA Script Announces the Commercial Launch of the SYNTAX System, the First Benchtop DNA Printer Powered by Enzymatic Synthesis, to Accelerate Molecular Biology and Genomics Workflows The SYNTAX System Prints DNA on Demand, Bringing Workflow Control Back to the Lab SOUTH SAN FRANCISCO, Calif., and PARIS, June 15, 2021 - DNA Script, a pioneer in DNA printing on demand, today announced the commercial launch of their SYNTAX platform with their first product, the SYNTAX System ... 09/06/2021 Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies STRASBOURG, France and PHILADELPHIA, June 9, 2021 /PRNewswire/ -- Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today that the US Food and Drug Adm ... 08/06/2021 Omnidoc annonce avoir finalisé une levée de fond de 3 millions d’euros pour développer sa solution de téléexpertise Ce premier tour de table est mené par Kurma Partners et Newfund, avec la participation de business angels et de la BPI L’enjeu principal de la levée est de développer la solution afin qu’elle s’adapte à l’ensemble des professionnels ... 08/06/2021 Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling Stockholm, 8 June 2021 - The US Patent and Trademark Office has granted a patent for Sepranolone for the treatment of Tourette, Obsessive-Compulsive Disorder (OCD) and pathological gambling. CEO Peter Nordkild: “The powerful neurosteroid Allopregnanolone (ALLO) seems to be the missing link in ... 03/06/2021 Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases Mataró, Barcelona, Spain, June 3, 2021 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating ... 21/05/2021 SmartCatch raises EUR 3.2 Million in Seed financing to accelerate the development of its flagship solution in liquid biopsy KURMA Partners, IRDI Capital Investissement and M-Capital have acquired a stake in SmartCatch, a French medtech and deeptech company specialized in the development of cutting-edge diagnostic tools for precision medicine. The capital operation aims to accelerate the company's growth and the devel ... 19/05/2021 Asarina Pharma receives approval of CTA for phase IIa Tourette study Stockholm, 19 May, 2021 - Asarina Pharma’s Clinical Trial Application for a phase IIa study with Sepranolone in Tourette Syndrome has been approved by the Danish Medical Agency, with the study to commence in August 2021 at two sites in Denmark. With Cognitive Behavioral Therapy as firs ... 17/05/2021 Arkhn raises €4 million to lead healthcare institutions towards sovereign and efficient data management Newfund and Kurma Partners led this first round of financing. The funds raised will support Arkhn's strong growth and the deployment of its data architecture solutions in France and Europe. Data interoperability is critical to improve care, support research, and make hospitals m ... 29/04/2021 Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis Mirum expands potential opportunities across rare disease pipeline Vivet to lead preclinical development of its two gene therapy programs for PFIC3 and PFIC2 Mirum gains option to license VTX-803 and VTX-802 FOSTER CITY, Calif. and PARIS, France - March 12, 2021 - Mirum Pharmaceuticals ... 24/03/2021 Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies Archamps, France, 24th March 2021 – Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joini ... 19/03/2021 Mila lance une étude clinique à échelle internationale sur les bénéfices du rythme pour les enfants atteints des troubles spécifiques des apprentissages et du langage Soutenue par Kurma Partners, BNP Paribas Développement et Bpifrance via son fonds Patient Autonome, la jeune entreprise va valider cliniquement sa solution pour améliorer le quotidien des patients et le suivi thérapeutique des professionnels de santé Paris, le 17 mar ... 16/03/2021 Asarina Pharma AB (publ) Annual Report 2020 released Asarina Pharma CEO Peter Nordkild: “2020 and early 2021 have seen new research and additional data confirming and consolidating the efficacy and potential of our flagship compound Sepranolone. As we continue forward into an eventful 2021, we remain confident of the significant clinical relevan ... 11/03/2021 Asceneuron Receives USD 2.2 Million Award from the Alzheimer’s Drug Discovery Foundation Award will fund first in human clinical trials of next generation O-GlcNAcase inhibitor, ASN51, to start Q2 2021 Lausanne, SWITZERLAND and San Francisco, CA, USA, 9 March, 2021 - Asceneuron SA, an emerging leader in the development of treatments for neurodegenerative diseases, announced today t ... 02/03/2021 Argobio announces its launch with 50 M€ to create and develop pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur Argobio is a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years Argobio has 50 M€ of share capital committed by a syndicate of complementary and strategic investors with a shared goal to develop some of Europe&r ... 15/02/2021 New preclinical study confirms that Sepranolone suppresses tics in Tourette Syndrome (Stockholm, 11 February 2021.) Two sets of new preclinical data presented by Prof Marco Bortolato (Univ. of Utah) confirm that Sepranolone suppresses tics in Tourette Syndrome (TS) and restores Prepulse Inhibition (PPI), a key phenomenon related to TS with no observable side-effects. The new data al ... 10/02/2021 MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman MedLumics’ oversubscribed financing round closes at EUR 18M to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation MedTech veteran, Rich Ferrari, joins MedLumics’ Board of Directors as new Chairman Madrid, Spain ... 05/02/2021 Kurma Partners announces the pricing of Pharvaris IPO Paris, Friday 5th February - Kurma Partners a key European player in the financing of innovation in healthcare and biotechnology are proud to announce the successful IPO of one for which Kurma Partners acted as founder investor together with Life Sciences Partners (LSP) in 2016 : Pharvaris. Pharv ... 26/01/2021 Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN) Largest prospective efficacy study conducted in the orphan disease AMN Leriglitazone significantly reduces progression of cerebral lesions and myelopathy symptoms Minoryx preparing for discussions with regulators for approval of leriglitazone for AMN patients Mataró, Barcelona, ... 13/01/2021 IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology Copenhagen, Denmark - January 13, 2021: IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. The financing round wa ... 07/01/2021 AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial • First patients with COVID-19 enrolled in the REVIVAL Phase III study • COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600 SA-AKI patients overall • RVO, an agency of the ... 07/01/2021 Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Lyon, France, and Cambridge, MA, January 6, 2021 - Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to AZP-3601, the com ... ABOUT KURMA TEAM OUR FUNDS PORTFOLIO NEWS VIDEOS CONTACT FOLLOW US CONTACT@KURMAPARTNERS.COM Tél: +33 (0)1 84 86 08 61 24, rue Royale 75008 Paris France © COPYRIGHT KURMA PARTNERS. LEGAL NOTICE REGULATORY INFORMATION PRIVATE POLICY DESIGN : AGENCE K2